A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Phase of Trial: Phase III
Latest Information Update: 06 Dec 2019
Price : $35 *
At a glance
- Drugs Venetoclax (Primary) ; Ibrutinib; Obinutuzumab
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 14 Jan 2019 Status changed from not yet recruiting to recruiting.
- 01 Jan 2019 Planned initiation date changed from 19 Dec 2018 to 7 Jan 2019.
- 17 Oct 2018 New trial record